Phio Pharmaceuticals (PHIO) vs Rocket One (RKTO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Phio Pharmaceuticals (PHIO) has outperformed Rocket One (RKTO) over the past year, losing 41.4% versus a loss of 72.6%. Over five years, RKTO leads with a -98.6% price change compared with -99.6% for PHIO. Phio Pharmaceuticals is the larger company by market cap ($7.8 million vs $7.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PHIO | RKTO |
|---|---|---|
| Share price | $0.656 | $0.297 |
| Market cap | $7.84M | $7.39M |
| 1-day change | -8.25% | +5.24% |
| YTD return | -37.52% | -70.00% |
| 1-year return | -41.43% | -72.63% |
| 5-year return | -99.56% | -98.60% |
| EPS (TTM) | $-1.21 | $-0.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-8.70M | $-12.47M |
| 52-week high | $1.88 | $2.45 |
| 52-week low | $0.6395 | $0.26 |
| Distance from 52-week high | -65.11% | -87.88% |
| Analyst consensus | none | — |
| Avg. price target upside | +2034.15% | — |
| Average volume | 106.09K | 338.12K |
| Shares outstanding | 11.95M | 24.90M |
| Employees | 6 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHIO has outperformed RKTO by 31.2 percentage points over the past year.
About Phio Pharmaceuticals
PHIO stock →Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Rocket One
RKTO stock →Rocket One Inc. focuses on developing and commercializing AI semiconductor infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PHIO vs RKTO FAQ
Which is bigger, Phio Pharmaceuticals or Rocket One?
Phio Pharmaceuticals (PHIO) is larger, with a market capitalization of $7.84M compared with $7.39M for Rocket One (RKTO).
Which stock has performed better over the past year, PHIO or RKTO?
PHIO returned -41.43% over the past 12 months, compared with -72.63% for RKTO (price return, excluding dividends). Past performance does not predict future results.
Are Phio Pharmaceuticals and Rocket One in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.